← Back to headlines
Bicara Gains Buy Rating for Cancer Drug Ficera's SoC Potential
Bicara has been given a buy rating by Bank of America, which sees significant System-on-Chip (SoC) potential in the company's cancer drug, Ficera.
Sources
Showing 0 of 1 sources
No articles available in your preferred languages.
1 article available in other languages below.
